PubRank

Peter B Berger

Author PubWeight™ 236.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 18.25
2 Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 11.06
3 Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011 6.39
4 Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002 4.99
5 Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006 4.18
6 Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005 4.16
7 The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 3.74
8 Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008 3.68
9 Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003 3.38
10 Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv 2010 3.24
11 Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013 3.17
12 Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011 3.16
13 Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003 3.13
14 A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004 3.07
15 Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005 3.05
16 Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011 2.98
17 Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005 2.59
18 Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007 2.56
19 Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004 2.55
20 Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol 2007 2.47
21 ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002 2.46
22 Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004 2.42
23 Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008 2.38
24 Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2004 2.29
25 Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004 2.21
26 Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). Circulation 2003 2.21
27 Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 2003 2.17
28 ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery--Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg 2002 2.11
29 Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA 2007 2.10
30 Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med 2012 2.09
31 ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2002 2.08
32 The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002 2.03
33 Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. Circulation 2008 2.01
34 Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009 1.77
35 Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009 1.76
36 Readmission in the 30 days after percutaneous coronary intervention. JACC Cardiovasc Interv 2013 1.63
37 Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 2002 1.62
38 Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 2006 1.61
39 Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J 2004 1.60
40 Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood 2002 1.59
41 Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv 2011 1.56
42 Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation 2006 1.55
43 Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J 2010 1.55
44 Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J 2004 1.47
45 Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2011 1.47
46 One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. Eur Heart J 2007 1.47
47 One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. EuroIntervention 2013 1.47
48 The New York State risk score for predicting in-hospital/30-day mortality following percutaneous coronary intervention. JACC Cardiovasc Interv 2013 1.45
49 Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med 2003 1.44
50 Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. Circ Cardiovasc Qual Outcomes 2009 1.43
51 Incidence, correlates, management, and clinical outcome of coronary perforation: analysis of 16,298 procedures. Am Heart J 2004 1.43
52 ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time. Am Heart J 2009 1.42
53 Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003 1.41
54 Percutaneous coronary intervention for ST-segment and non-ST-segment elevation myocardial infarction at hospitals with and without on-site cardiac surgical capability. Mayo Clin Proc 2004 1.40
55 Systems of care for ST-segment-elevation myocardial infarction: a report From the American Heart Association's Mission: Lifeline. Circ Cardiovasc Qual Outcomes 2012 1.39
56 The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. Urology 2013 1.39
57 Safety and efficacy of cutting balloon angioplasty: the Mayo Clinic experience. J Invasive Cardiol 2002 1.39
58 In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry. Catheter Cardiovasc Interv 2012 1.38
59 Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008 1.37
60 Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation 2005 1.30
61 Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 2003 1.27
62 Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007 1.25
63 Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. J Am Coll Cardiol 2011 1.23
64 Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011 1.20
65 Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. J Interv Cardiol 2013 1.10
66 The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008 1.10
67 The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol 2009 1.07
68 Pro: standard percutaneous coronary intervention is the procedure of choice for myocardial revascularization. J Cardiothorac Vasc Anesth 2003 1.07
69 Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008 1.07
70 Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009 1.03
71 Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation 2005 1.03
72 Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol 2006 1.03
73 Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006 1.02
74 The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J 2012 1.02
75 Allergic reactions to clopidogrel and cross-reactivity to other agents. Curr Allergy Asthma Rep 2011 1.01
76 Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J 2004 1.00
77 Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol 2003 0.99
78 Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002 0.98
79 Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc 2013 0.97
80 Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. Circ Cardiovasc Interv 2013 0.96
81 Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial. Am J Cardiol 2010 0.96
82 Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004 0.95
83 Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). Am J Cardiol 2004 0.95
84 Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention. J Thromb Thrombolysis 2013 0.95
85 Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant 2005 0.95
86 Risk stratification for long-term mortality after percutaneous coronary intervention. Circ Cardiovasc Interv 2014 0.92
87 Clinical safety of magnetic resonance imaging early after coronary artery stent placement. J Am Coll Cardiol 2003 0.92
88 Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. Circ Cardiovasc Interv 2009 0.91
89 Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J 2009 0.91
90 Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. Atherosclerosis 2003 0.90
91 Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design. Am Heart J 2006 0.89
92 Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. J Invasive Cardiol 2007 0.89
93 Alveolar hemorrhage associated with periprocedural eptifibatide administration. J Invasive Cardiol 2004 0.88
94 Optimal duration of clopidogrel use after implantation of drug-eluting stents--still in doubt. N Engl J Med 2010 0.87
95 Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004 0.87
96 Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007 0.86
97 Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. J Am Coll Cardiol 2004 0.86
98 Assessing the current role of platelet function testing. Clin Cardiol 2008 0.86
99 Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 2009 0.85
100 Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery disease. Mayo Clin Proc 2007 0.85
101 Age dependence of the influence of methylenetetrahydrofolate reductase genotype on plasma homocysteine level. Am J Epidemiol 2003 0.84
102 Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal. J Am Coll Cardiol 2002 0.84
103 Routine intravascular ultrasound scanning guidance of coronary stenting is not associated with improved clinical outcomes. Am Heart J 2004 0.84
104 In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction. Am J Cardiol 2005 0.84
105 Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Circ Cardiovasc Interv 2012 0.83
106 Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J 2009 0.83
107 Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention 2015 0.83
108 Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clin Res Cardiol 2007 0.83
109 Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acid. Atherosclerosis 2002 0.82
110 Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. Circ Cardiovasc Interv 2009 0.82
111 Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). Am J Cardiol 2006 0.82
112 Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. Am Heart J 2011 0.81
113 The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol 2008 0.81
114 Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol 2008 0.79
115 Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. Am J Cardiol 2004 0.79
116 One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J 2005 0.79
117 Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. J Thromb Thrombolysis 2005 0.78
118 Does kidney function alter the benefit of reperfusion therapy for ST-segment elevation myocardial infarction? JACC Cardiovasc Interv 2009 0.78
119 Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. Am Heart J 2007 0.78
120 Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. Am J Cardiol 2009 0.78
121 Antiplatelet therapy and platelet function testing. Clin Cardiol 2008 0.77
122 Distal protection devices during percutaneous coronary and carotid interventions. Curr Control Trials Cardiovasc Med 2001 0.77
123 Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). Am J Cardiol 2009 0.77
124 Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. J Thromb Thrombolysis 2007 0.77
125 Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. Am J Cardiol 2005 0.77
126 Frequency of coronary angiography and revascularization among men and women with myocardial infarction and their relationship to mortality at one year: an analysis of the Geisinger myocardial infarction cohort. J Interv Cardiol 2012 0.77
127 Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol 2008 0.77
128 The thienopyridines. J Interv Cardiol 2002 0.77
129 Bleeding is bad.... isn't it? Circulation 2007 0.77
130 Do stents reduce mortality compared with balloon angioplasty? A critical review of all the evidence. Am Heart J 2005 0.77
131 P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when? Curr Cardiol Rep 2011 0.76
132 Aspirin following PCI: too much of a good thing? Eur Heart J 2009 0.76
133 Frequency and time course of reocclusion and restenosis in coronary artery occlusions after balloon angioplasty versus Wiktor stent implantation: results from the Mayo-Japan Investigation for Chronic Total Occlusion (MAJIC) trial. Am Heart J 2004 0.76
134 A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2005 0.76
135 Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals. Pharmacotherapy 2006 0.76
136 Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. Clin Res Cardiol 2011 0.76
137 Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol 2003 0.75
138 Emergency pretreatment for contrast allergy before direct percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol 2008 0.75
139 Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction. Evid Based Med 2006 0.75
140 Review: reduction in resting heart rate after taking beta-blockers or calcium-channel blockers reduce mortality and morbidity after MI. Evid Based Med 2008 0.75
141 Intracoronary glycoprotein IIb/IIIa inhibitors from questioning the logic to weighing the data. JACC Cardiovasc Interv 2010 0.75
142 Perindopril reduced cardiac events in stable coronary artery disease. ACP J Club 2004 0.75
143 Does clopidogrel pretreatment counteract the benefits of off-pump CABG surgery? Nat Clin Pract Cardiovasc Med 2006 0.75
144 Can euphoria be bad? J Am Coll Cardiol 2003 0.75
145 Bivalirudin reduced major bleeding and adverse events in patients with STEMI having PCI. ACP J Club 2008 0.75
146 The glycoprotein IIb/IIIa inhibitor wars: an update. J Am Coll Cardiol 2010 0.75
147 A radial resolution to a warfarin worry. Catheter Cardiovasc Interv 2015 0.75
148 Diabetes mellitus and preferred method of coronary revascularization--the debate continues. J Invasive Cardiol 2003 0.75
149 Review: early statin therapy does not reduce the composite endpoint of death, MI, or stroke in acute coronary syndromes. ACP J Club 2006 0.75
150 Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot? Catheter Cardiovasc Interv 2008 0.75
151 Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis 2008 0.75
152 Reply: Is CABG Superior to DES for Repeat Revascularization in Patients With Isolated Proximal LAD Disease? J Am Coll Cardiol 2015 0.75
153 Cardiogenic shock--Beyond the large infarction. Crit Care Med 2006 0.75
154 Adjunctive treatment with eplerenone reduced 30-day all-cause mortality in acute myocardial infarction. ACP J Club 2006 0.75
155 Treatment of coronary bifurcations: might less be more? Eur Heart J 2008 0.75
156 Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010 0.75
157 Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol 2008 0.75
158 Appending Limited Clinical Data to an Administrative Database for Acute Myocardial Infarction Patients: The Impact on the Assessment of Hospital Quality. Med Care 2016 0.75
159 GUSTO V: should it affect clinical practice? Global Use of Strategies to Open Occluded Coronary Arteries. Cleve Clin J Med 2002 0.75
160 Assessing hospital performance for acute myocardial infarction: how should emergency department transfers be attributed. Med Care 2015 0.75
161 Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. JACC Cardiovasc Interv 2010 0.75
162 Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. Am Heart J 2005 0.75
163 Modulating thrombotic potential in catheter-based percutaneous coronary and peripheral vascular interventions. J Thromb Thrombolysis 2004 0.75
164 Feasibility and safety of ad hoc percutaneous coronary intervention in the modern era. J Invasive Cardiol 2009 0.75
165 Transport and centralization of acute coronary syndrome care. Curr Cardiol Rep 2004 0.75
166 Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study. J Thromb Thrombolysis 2004 0.75
167 Paramedic transtelephonic communication to cardiologist of clinical and electrocardiographic assessment for rapid reperfusion of ST-elevation myocardial infarction. J Electrocardiol 2007 0.75
168 Can percutaneous coronary interventions reduce death and myocardial infarction in stable and unstable coronary disease? Catheter Cardiovasc Interv 2004 0.75
169 The risk of drug-eluting stent thrombosis with noncardiac surgery. Curr Cardiol Rep 2007 0.75
170 Therapeutic goals for effective platelet inhibition: a consensus document. Rev Cardiovasc Med 2006 0.75
171 Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol 2008 0.75
172 Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial. J Invasive Cardiol 2011 0.75
173 Cutting balloon angioplasty vs. conventional balloon angioplasty in patients receiving intracoronary brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv 2004 0.75
174 Assessment of advantages and disadvantages of agents used for therapeutic anticoagulation. Dis Mon 2012 0.75